辅助生殖技术受孕的子代在青春期和成年早期甲状腺功能正常
本前瞻性队列研究比较了辅助生殖技术(ART)受孕与自然受孕青少年及年轻成人的甲状腺功能,发现两组甲状腺功能均值均在正常范围,亚临床及临床甲状腺功能异常患病率无差异,游离三碘甲状腺原氨酸(fT3)和游离甲状腺素(fT4)的微小差异被认为无生物学相关性。
要点
- 14岁和20岁时,ART子代与自然受孕子代的促甲状腺激素(TSH)浓度均无差异。
- 14岁时ART组fT3较低(4.80 vs 5.35 pmol/L,P<0.001),fT4较高(12.76 vs 12.19 pmol/L,P<0.001)。
- 20岁时ART组fT3和fT4较高(4.91 vs 4.63 pmol/L,P=0.012;13.43 vs 12.45 pmol/L,P<0.001)。
核心结论
- 本研究未发现ART受孕与自然受孕的青少年和年轻成人在甲状腺功能方面存在临床相关差异。
- 检测到的fT3和fT4微小差异被认为无生物学相关性。
- 作者认为这些发现令人安心,但需要在成年期重新研究。
研究设计与样本
- Growing Up Healthy Study(GUHS)为前瞻性队列研究,旨在招募1991年至2001年间在研究地区经ART受孕出生的所有青少年。
- 纳入的GUHS参与者(n=303,年龄13-20岁)完成健康评估,根据入组年龄在14岁或20岁随访时完成甲状腺评估。
- 甲状腺评估结果与Raine Study Generation 2(Gen2)中自然受孕的参与者(n=2868,出生于1989年至1992年)进行比较。
- 14岁时比较GUHS n=134与Gen2 n=1359;20岁时比较GUHS n=47与Gen2 n=914。
主要发现
- 所有甲状腺功能均值均在正常范围内。
- 14岁时,GUHS青少年相比Gen2青少年fT3较低(4.80 vs 5.35 pmol/L,P<0.001),fT4较高(12.76 vs 12.19 pmol/L,P<0.001)。
- 20岁时,GUHS青少年相比Gen2参与者fT3较高(4.91 vs 4.63 pmol/L,P=0.012),fT4较高(13.43 vs 12.45 pmol/L,P<0.001)。
- 14岁和20岁时,两组间亚临床及临床甲状腺功能减退和亢进或甲状腺自身免疫的患病率均无差异。
- 新鲜胚胎移植(ET)与冻融胚胎移植(FET)之间的甲状腺功能无差异,母体峰值雌二醇(pE2)与fT4之间无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究的观察性性质限制了证明因果关系的能力。
- 20岁时比较ET和FET子代可能缺乏把握度。
- 由于研究时ICSI周期数少,无法区分不同ART类型(如IVF与ICSI)。
- ART实验室和临床数据与治疗同时收集,未回顾性收集其他ART周期数据,因此一些因素无法纳入分析。
- 作者指出这些发现需要在成年期重新研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there differences in thyroid function between adolescents and young adults conceived with and without ART? SUMMARY ANSWER: This study demonstrated no evidence of clinically relevant differences in thyroid function between adolescents and young adults conceived with and without ART. WHAT IS KNOWN ALREADY: Studies to date have reported an increase in subclinical hypothyroidism in offspring conceived after ART. It has been suggested that the increase in maternal estrogen (E2) after fresh embryo transfers could affect thyroid function of the offspring. Suboptimal thyroid function at a young age can cause irreversible damage to the central nervous system, which makes early detection and correct treatment essential. STUDY DESIGN, SIZE, DURATION: The Growing Up Healthy Study (GUHS) is a prospective cohort study, which aimed to recruit all adolescents born after conception with ART between 1991 and 2001 in the study area. The included participants (n = 303, aged 13-20 years) completed various health assessments. Depending on the age at enrolment, participants completed thyroid assessments at the 14- or 20-year follow-up. The outcomes of these replicated thyroid assessments were compared to those of participants conceived without ART from the Raine Study Generation 2 (Gen2). The Gen2 participants (n = 2868) were born between 1989 and 1992 and have been recognized to be representative of the local population. PARTICIPANTS/MATERIALS, SETTING, METHODS: Thyroid function assessments were compared between n = 134 GUHS and n = 1359 Gen2 adolescents at age 14 years and between n = 47 GUHS and n = 914 Gen2 young adults at age 20 years. The following mean thyroid hormone concentrations were compared between the cohorts: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4) and thyroid peroxidase antibodies (TPOAb). The prevalence of the following thyroid hormone profiles, based on individual thyroid hormone concentrations, was compared: euthyroidism, subclinical and overt hypo- and hyperthyroidism and thyroid autoimmunity. Outcomes were compared between the cohorts, and univariately between fresh embryo transfers (ET) and frozen ET (FET) within the GUHS. The correlation between maternal peak E2 concentrations (pE2) and fT4 was assessed within the GUHS. MAIN RESULTS AND THE ROLE OF CHANCE: All mean thyroid function outcomes fell within the normal range. At both ages, we report no differences in TSH concentrations. At age 14 years, lower fT3 concentrations (4.80 versus 5.35 pmol/L, P < 0.001) and higher fT4 concentrations (12.76 versus 12.19 pmol/L, P < 0.001) were detected in the GUHS adolescents compared to Gen2 adolescents. At age 20 years, higher fT3 and fT4 concentrations were reported in GUHS adolescents (4.91 versus 4.63 pmol/L, P = 0.012; 13.43 versus 12.45 pmol/L, P < 0.001, respectively) compared to Gen2 participants. No differences in the prevalence of subclinical and overt hypo- and hyperthyroidism or thyroid autoimmunity were demonstrated between the cohorts at age 14 and 20 years. Thyroid function did not differ between ET and FET, and no correlation between pE2 and fT4 was reported. LIMITATIONS, REASONS FOR CAUTION: The observational nature of the study limits the ability to prove causation. Furthermore, the comparison of ET and FET offspring at age 20 years may be lacking power. We were unable to differentiate between different types of ART (e.g. IVF versus ICSI) owing to the low number of ICSI cycles at the time of study. As ART laboratory and clinic data were collected contemporaneously with the time of treatment, no other data pertaining to the ART cycles were sought retrospectively; hence, some factors could not be accounted for. WIDER IMPLICATIONS OF THE FINDINGS: This study does not support previous findings of clinically relevant differences in thyroid function when comparing a cohort of adolescents conceived after ART to counterparts conceived without ART. The minor differences detected in fT3 and fT4 were considered not biologically relevant. Although these findings appear reassuring, they warrant reinvestigation in adulthood. STUDY FUNDING/COMPETING INTERESTS: This project was funded by an NHMRC Grant (Hart et al., ID 1042269). R.J.H. is the Medical Director of Fertility Specialists of Western Australia and a shareholder in Western IVF. He has received educational sponsorship from MSD, Merck-Serono and Ferring Pharmaceuticals. P.B. is the Scientific Director of Concept Fertility Centre, Subiaco, Western Australia. J.L.Y. is the Medical Director and a shareholder of PIVET Medical Centre, Perth, Western Australia. TRIAL REGISTRATION NUMBER: N/A.
引用
- Wijs LA, Doherty DA, Keelan JA, et al. Offspring conceived through ART have normal thyroid function in adolescence and as young adults. Hum Reprod. 2022. PMID: 35526152. doi:10.1093/humrep/deac095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。